NCT06627309 2026-03-09
Rapid dFLC Response Predict CHR in AL Amyloidosis
Peking University People's Hospital
Recruiting
Clinical Trials
8 trialsNCT07206810 2025-10-03
A Study of the Bortezomib, Lenalidomide, and Dexamethasone Regimen for the Treatment of Newly Diagnosed Multiple Myeloma Patients
The First Affiliated Hospital of Soochow University
Completed
NCT06163040 2025-07-31
A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan
Bristol-Myers Squibb
Completed
NCT04458831 2025-06-27
IONA-MM
Sanofi
Active not recruiting
NCT02555839 2025-03-28
Treatment of Relapsed/Refractory Multiple Myeloma (rrMM) With Pomalidomide in Clinical Practice
Celgene
Completed
NCT05495620 2022-08-10
Long-term KRd in Relapsed and/or Refractory Multiple Myeloma
Dong-A University Hospital
Unknown
NCT01540812 2020-03-09
Treatment of Acute Lymphoblastic Leukemia HIGH RISK BCR / ABL NEGATIVE IN ADULTS
PETHEMA Foundation
Completed
NCT02556905 2017-12-04
A Study to Collect and Evaluate the Safety and Efficacy Information of Korean Multiple Myeloma Patients Treated With REVLIMID®, After Approval of Marketing Authorization for New Drug in Korea
Celgene
Completed